|
|
|
| Expression and clinical significance of miR-155 and HER-3 in breast cancer |
| JI Xiaonan LI Yong LI Enjie |
| Department of General Surgery, Benxi Central Hospital, Liaoning Province, Benxi 117000, China |
|
|
|
Abstract Objective To investigate the expression of microRNA-155 (miR-155) and human epidermal growth factor receptor-3 (HER-3) in breast cancer tissues and to analyze their relationship with clinical data. Methods A total of 87 cases of breast cancer who treated in Benxi Central Hospital of Liaoning Province from March 2016 to August 2019 were selected as study objects. Quantitative real-time PCR was used to detect the expression of miR-155 in breast cancer tissues and adjacent tissues. Immunohistochemistry was used to detect the expression of HER-3. The expression of miR-155 and HER-3 and their relationship with clinical data were analyzed, and the correlation between miR-155 and HER-3 was analyzed. Results The relative expression levels of miR-155 and HER-3 in breast cancer tissues were higher than those in adjacent tissues, and the difference were highly statistically significant (all P < 0.01). The expression of miR-155 and HER-3 in breast cancer tissues with different degree of tumor cell differentiation, TNM stage and lymph node metastasis had statistical significance (P < 0.05). There was a positive correlation between miR-155 and HER-3 expression in breast cancer tissues (r = 0.576, P < 0.05). Conclusion The expression levels of miR-155 and HER-3 in breast cancer tissues are elevated, which are related to tumor TNM stage, differentiation degree and lymphatic metastasis, and are expected to become a new biomarker to guide the diagnosis and treatment of breast cancer.
|
|
|
|
|
|
[1] 张雨薇，张馨月，白立川，等.ceRNA调控miR-145-5p介导肿瘤发生发展的研究进展[J].现代肿瘤医学，2020， 28（10）：1766-1769.
[2] 杨鑫苗，张永强.miRNA调控实体肿瘤发生发展机制研究进展[J].现代肿瘤医学，2020，28（9）：1587-1589.
[3] 潘虹，邹剑铭，张英，等.MicroRNAs在乳腺癌干细胞中的作用研究进展[J].现代肿瘤医学，2015，23（17）：2521-2525.
[4] 马志勇，李雪平，侯振宇，等.MiRNA-155通过调控β-catenin促进结肠癌SW480细胞的侵袭[J].现代生物医学进展，2018，18（12）：2242-2247.
[5] 闫东.人表皮生长因子受体3在人表皮生长因子受体2阳性乳腺癌组织中的表达[J].肿瘤基础与临床，2017，30（6）：535-537.
[6] 徐磊，孙志超，冯晓星.EGFR和HER-3在老年胃癌组织中的表达及其与预后的关系[J].临床与病理杂志，2018， 38（9）：1840-1845.
[7] Pearce L. Breast cancer [J]. Nurs Stand，2016，30（51）：15.
[8] 蔡婉.外泌体在乳腺癌中的研究进展[J].临床与病理杂志，2018，38（9）：1997-2002.
[9] 郝帅，赵健洁，张晓华，等.MicroRNA在乳腺癌耐药中的功能研究进展[J].中国医药导报，2020，17（2）：29-32.
[10] 杨鑫苗，张永强.miRNA在实体肿瘤诊断及治疗中的研究进展[J].癌症进展，2019，17（10）：1117-1119，1151.
[11] Liu F，Kong X，Lv L，et al. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes [J]. Cancer Lett，2015，359（2）：288-298.
[12] He XH，Zhu W，Yuan P，et al. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells [J]. Oncogene，2016， 35（46）：6015-6025.
[13] Sun Y，Wang M，Lin G，et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer [J]. PLoS One，2012，7（10）：e47003.
[14] 何同梅，陈丽芳，何时，等.MMP16在胰腺癌组织中的表达及其临床意义[J].临床与病理杂志，2016，36（10）：1600-1604.
[15] 王阳，杜俊峰，韩云峰.miR-155-5p通过调节SOX1的表达促进乳腺癌细胞系MCF-7的侵袭与迁移[J].华中科技大学学报：医学版，2017，46（5）：555-558.
[16] 任猛，高维实，杨勇，等.人类表皮生长因子受体家族在乳腺癌中的作用[J].医学综述，2015，21（7）：1211-1214.
[17] Olmez OF，Evrensel T，Cubukcu E，et al. Prognostic Significance of Human Epidermal Receptor （HER）-3 Immunohistochemical Expression in Patients with Metastatic Breast Cancer [J]. Asian Pac J Cancer Prev，2013，14（7）：4115-4119.
[18] 卢训西，国琳玮，李小光，等.PI3K/AKT/mTOR通路及其抑制剂在乳腺癌中的应用现状[J].中国癌症杂志，2020，30（2）：154-160.
[19] 罗思佳，张建新，张智勇，等.乳腺癌miR-155表达与临床病理特征的关系及与HER-3蛋白的相关性[J].华南国防医学杂志，2019，33（5）：312-315.
[20] 陈超英，陈苗苗，刘灵芝，等.趋化因子受体3对乳腺癌调控机制的探究及其临床意义[J].癌症进展，2019，17（8）：901-904.
[21] 刘彻，艾力·赛丁，苏鹏程.新辅助化疗对乳腺癌患者雌激素受体、孕激素受体、人表皮生长因子受体-2表达的影响[J].医疗装备，2019，32（14）：180-182.
[22] 詹琦，周晟，娄丽萍.EGFR，HER2和HER3在胆管癌中的表达及预后价值[J].实用肿瘤学杂志，2019，33（6）：491-496. |
|
|
|
